Roth Capital Bumps PT on Ligand Pharma (LGND) up to $149; Says Running on All Cylinders
Tweet Send to a Friend
Roth Capital lifts its price target on Buy-rated Ligand Pharma (Nasdaq: LGND) from $147 to $149 following Q2 results reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
